A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease

Gut

Volumn 62, Issue 9, 2013, Pages 1288-1294

  Sands, Bruce E ^a   Katz, Seymour ^b   Wolf, Douglas C ^c   Feagan, Brian G ^d,e   Wang, Tao ^f   Gustofson, Lisa Marie ^f   Wong, Cindy ^e   Vandervoort, Margaret K ^e   Hanauer, Stephen ^g  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Long Island Clinical Research   (United States)

^c Atlanta GI   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e ROBARTS RESEARCH INSTITUTE   (Canada)

^f OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; ADULT; AGED; APHERESIS; APHERESIS SYSTEM; ARTICLE; BACKACHE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; GASTROINTESTINAL ENDOSCOPY; GRANULOCYTE APHERESIS; HEADACHE; HEMATOLOGY EQUIPMENT; HEMATOMA; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOCYTE APHERESIS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION;

BLOOD COMPONENT REMOVAL; GRANULOCYTES; INFLAMMATORY BOWEL DISEASE; MONOCYTES; REMISSION INDUCTION;

ADULT; BLOOD COMPONENT REMOVAL; CROHN DISEASE; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GRANULOCYTES; HUMANS; MALE; MIDDLE AGED; MONOCYTES; PLACEBOS; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84881543502     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300995     Document Type: Article

References (33)

1. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008;14:354-77. (Pubitemid 351320845)
2. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:674-88.
3. Panés J, Gomollón F, Taxonera C, et al. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007;67:2511-37. (Pubitemid 350159165)
4. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 2008;10:568-75.
5. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996;16:144-50. (Pubitemid 26166392)
6. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and Il-1 by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81. (Pubitemid 23308385)
7. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000;120:241-6. (Pubitemid 30304217)
8. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, et al. Increased mucosal matrix metalloproteinaise-1, -2, -3, and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007;39:733-9. (Pubitemid 47053808)
9. Pavlick KP, Laroux FS, Fuseler J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002;33:311-22. (Pubitemid 34786271)
10. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflamed bowel disease. Gut 1992;33:773-8.
11. Maor I, Rainis T, Lanir A, et al. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease. Dig Dis Sci 2008;53:2208-14.
12. Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher 2003;7:48-59. (Pubitemid 36648043)
13. Matsui T, Nishimura T, Matake H, et al. Granulocytapheresis for Crohn's disease: a report of seven refractory patients. Am J Gastroenterol 2003;98:511-12. (Pubitemid 36232417)
14. Fukuda Y, Matsui T, Suzuki Y, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol 2004;39:1158-64. (Pubitemid 40074281)
15. Kusaka T, Fukunaga K, Ohnishi K, et al. Adsorptive monocyte- granulocytapheresis (M-GCAP) for refractory Crohn's disease. J Clin Apher 2004;19:168-73. (Pubitemid 40165056)
16. Giampaolo B, Giuseppe P, Michele B, et al. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: our experience with a prospective study. World J Gastroenterol 2006;12:2201-4.
17. Doménech E, Hinojosa J, Esteve-Comas M, et al. Granulocytapheresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004;20:1347-52. (Pubitemid 40040082)
18. Sands BE, Sandborn WJ, Wolf DC, et al. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol 2006;40:482-9. (Pubitemid 44318132)
19. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-9.
20. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
21. International Conference on Harmonisation. Good clinical practice: consolidated guidelines; notice of availability. Fed Regist 1996;62:25691-709.
22. Ware JE, Kosinski M, Keller KD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, 1994.
23. Yoshida EM. The Crohn's disease activity index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 1999;13:65-74.
24. EuroQol Group. EuroQol* - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
25. Lerner D, Amick BC 3rd, Rogers WH, et al. The Work Limitations Questionnaire. Med Care 2001;39:72-85.
26. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity of Crohn's disease: a prospective multicentre study. Gut 1989;30:983-9.
27. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:783-90.
28. Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12:558-65. (Pubitemid 43977736)
29. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with Infliximab. Ann Intern Med 2007;146:829-38. (Pubitemid 351650483)
30. Kawamura A, Saitoh M, Yonekawa M, et al. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease. Ther Apher 1999;3:334-7.
31. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 1995;30:322-9.
32. Sawada K, Ohnishi K, Kosaka T, et al. Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol 1995;30(Suppl 8):124-7.
33. Kosaka T, Sawada K, Ohnishi K, et al. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern Med 1999;38:102-11.